Drug intelligence / Profile preview

ASF subunit vaccine

Development stage: Preclinical
Lead developer: Reber Genetics
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Intranasal, Subcutaneous

Overview

ASF subunit vaccine is a veterinary vaccine candidate being developed by Reber Genetics for the prevention of African Swine Fever (ASF) in pigs. The vaccine utilizes a subunit platform based on cancer immunotherapy principles to deliver specific African Swine Fever virus (ASFV) antigens, aiming to stimulate a protective immune response. This recombinant protein-based approach is designed to offer a safe and effective means of controlling ASFV outbreaks in swine populations. The project is currently in the preclinical research and development phase.

Other names: African swine fever subunit vaccine

Targets

ASFV (African swine fever virus)

Beyond the preview

Go deeper on ASF subunit vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASF subunit vaccine.

Explore the full profile